

REMARKS

This paper is submitted in response to the Notice of Non-Compliant Amendment (“NCA”) mailed September 7, 2007 regarding Sequence Listing errors. The foregoing lists the errors that the Examiner has indicated were present in the Validation Report along with the Applicant’s corrections and/or response:

(1) The response listed under <160> was “4” while 10 sequences were shown in the submitted file. Applicant has corrected <160> to reflect the correct number of sequences (10).

(2) The second sentence of the <223> response must be moved to the second line of the <223> response due to §1.823 of the Sequence Rules. Applicant has added an additional Feature Listing to the 10th sequence to reflect the information indicated in the second sentence of the sequence’s prior <223> response.

(3) The Genus species for all sequences must be indicated in the <213> response. Applicant has corrected the improperly referenced <213> responses to reflect the proper Genus of the species’ referenced.

(4) The explanations for the Xaa’s at locations 7, 16, and 23 under sequence 8 are invalid due to multiple amino acids being represented by a single Xaa indicator. Applicant has corrected the sequence by removing the Xaa listings and inserting the full amino acid sequences represented in the prior sequence listing as “Xaa”.

(5) The explanations for the Xaa’s at locations 7, 16, and 23 under sequence 9 are invalid due to multiple amino acids being represented by a single Xaa indicator. Applicant has corrected the sequence by removing the Xaa indicators and subsequently adding a Feature Listing indicating that the maximum number of positions has been shown and that some may be missing, per the Examiner’s suggestion in the NCA.

(6) The Examiner has requested that the Applicant explain "hnRNP A1" in sequences 8 and 9. Applicant believes that the Examiner has made this request in error and directs the Examiner to the <223> responses of the Feature Listings under sequences 8 and 9 which define hnRNP A1 as "a human hnRNP core protein".


**STATEMENT REGARDING CONTENTS OF SEQUENCE LISTING
UNDER 37 CFR §§1.821- 1.825**

Applicants enclose a computer readable copy of the Sequence Listing for the instant application as well as a substitute paper copy of the Sequence Listing. In accordance with 37 CFR §1.821 and §1.825, Applicants' undersigned agent states that both the computer readable copy and the substitute paper copy of the Sequence Listing submitted herewith are the same, and include no new matter.

Applicants request a four-month extension of time to respond to Notice of Non-Compliant Amendment. The Commissioner is hereby authorized to charge any fee required with this communication to Deposit Account 11-0404.

Dated: January 9, 2008

Respectfully submitted,
KELLEY DRYE & WARREN LLP
Attorneys and Agents for Applicants

By: 
Hans-Peter G. Hoffmann, Reg. No. 37,352
JOHN N. COULBY, Reg. No. 43,565
3050 K Street, N.W., Suite 400
Washington D.C. 20007
Tel. (202) 342-8400